Analyst Research Report Snapshot

Title:

CONSORT MEDICAL - INHALING IS TO BE ENCOURAGED

Price:

$10.00

Provider:

Edison Investment Research

Date:

23 Apr 2013

Pages:

12

Type:

AcrobatPDF

Companies referenced:

CSRT.L BAMExm.BRQ BIOC.CA BVC.L GLAX.KA GLAX.NS GLSK.DH GLSM.NS GSK.L

Available for Immediate Download
Summary:

Consort Medical’s outlook now rests on the Bespak division, but new product visibility has traditionally been low and the commercial prospects of the pipeline have been difficult to assess. Three recent posters (presented at a Boston symposium) have drawn our attention to the Oxette nicotine inhaler device and we detail them in this note. We believe Oxette could become Bespak’s largest revenue contributor over the medium term.

Why buy analyst research?

  • Institutional quality research
  • Available for Immediate Download
  • Detailed company or industry insight
  • Print or save
  • 24 hour customer support
Return to previous page without adding this item to your cart.
Email Customer Support.

About Analyst Research

Analyst research reports are available for immediate download after purchase. You will have unlimited access to the report for 24 hours after purchase, to download, print or save it as many times as you wish. Analyst Research provided by Reuters does not constitute investment advice, and is not endorsed by Reuters Research. This information is protected by copyright and intellectual property laws. More information on Analyst Research.